Neuropace, Inc. ((NPCE)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: The RNS System LGS Feasibility Study, officially titled RNS System Feasibility Study of Thalamocortical Brain-Responsive Neurostimulation for the Treatment of Lennox-Gastaut Syndrome, aims to gather preliminary safety and effectiveness data for brain-responsive neurostimulation. This study targets individuals aged 12 or older with Lennox-Gastaut Syndrome (LGS) who do not respond to antiseizure medications. The goal is to assess the feasibility of a larger pivotal study to expand the RNS System’s use for treating medically intractable LGS.
Intervention/Treatment: The study tests the RNS System, a device providing closed-loop responsive brain stimulation. It monitors brain activity to detect and prevent seizures by delivering electrical stimulation through leads when abnormal activity is identified.
Study Design: This Phase 2 interventional study uses a randomized, crossover model with double masking for participants and care providers. The primary purpose is treatment, focusing on the effectiveness of the RNS System in reducing seizure frequency.
Study Timeline: The study began on March 29, 2022, with the latest update submitted on August 13, 2025. These dates are crucial for tracking the study’s progress and ensuring timely updates for stakeholders.
Market Implications: This update could positively influence NeuroPace, Inc.’s stock performance by demonstrating progress in developing treatments for LGS, a challenging condition. Success in this study could enhance investor confidence and position the company favorably against competitors in the neurological treatment market.
The study is ongoing, with further details available on the ClinicalTrials portal.